Digoxin 0.25 mg
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Chun-Yao Huang, ViiV Healthcare, Tanta University, University of Monastir
Conditions
Atrial FibrillationHIV InfectionsHealthyHeart FailureIvabradineLeft Atrial RhythmRheumatoid Arthritis
Phase 1
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.
CompletedNCT01714206
Start: 2009-06-30End: 2009-09-30Updated: 2012-11-19
Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
CompletedNCT04425902
Start: 2020-12-16End: 2021-03-10Updated: 2024-01-05
A Phase 1 Study of PROT-001.
CompletedNCT06981299
Start: 2025-05-29End: 2025-12-23Updated: 2026-01-30
Phase 2
Phase 3
Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
NCT04308031
Start: 2018-08-26End: 2020-12-31Target: 100Updated: 2020-03-13
Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker
NCT05540600
Start: 2022-09-12End: 2023-12-01Target: 30Updated: 2022-09-16